The Institute for Experimental Tumour Research was founded in July 2009 as an institute of the Comprehensive Cancer Center Ulm (CCCU) with the primary aim of advancing translational and clinical research in the field of haematology and oncology. The work of our group concentrates primarily on research into the mechanisms of tumour development, with acute leukaemia in particular serving as a model disease for tumourigenesis.
A further focus is clinical research and the initiation and coordination of multicentre randomised studies in the field of indolent B-cell lymphomas (in particular Waldenstrom's disease and marginal zone lymphomas). The Medical Director coordinates the European Consortium for Waldenström's disease, the National Marginal Zone Lymphoma Registry (MZoL Registry for short), the National Follicular Lymphoma Registry (FL Registry), is the coordinator for national and European therapy guidelines for haematological neoplasms and is also actively involved in patient care at the University Hospital in the Department of Internal Medicine III (Haematology/Oncology).
In student teaching, the Institute teaches and supervises students from the fields of human medicine, molecular medicine and biology. In addition, the Institute is involved in the training of doctoral students at the "International Graduate School in Molecular Medicine" at Ulm University. The Institute is responsible for designing the "Interdisciplinary Oncology" module for the international part-time Master's programme in Advanced Oncology for postgraduates.
Institute Director Prof. Dr med. Christian Buske
Phone: 0731 500-65801
Ulm University Hospital
Albert-Einstein-Allee 23
89081 Ulm
Secretariat:
Sarah Schmeller
Phone: 0731 500-65801
Fax: 0731 500-65822
Email: sarah-anna.schmeller@uni-ulm.de
Jonas Häge
Phone: 0731 500-65888
Fax: 0731 500-65822
Email: jonas.haege@uni-ulm.de
News and events
Jul
Studie am Universitätsklinikum Ulm zeigt hohe Wirksamkeit und exzellente Verträglichkeit einer milden Immunchemotherapie bei Morbus Waldenström